Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor

J Clin Oncol. 2013 Feb 10;31(5):e57-8. doi: 10.1200/JCO.2012.44.5106. Epub 2013 Jan 7.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage
  • Amlodipine / administration & dosage
  • Angioedema / chemically induced*
  • Angioedema / drug therapy
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects*
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / adverse effects*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Calcium Channel Blockers / administration & dosage
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / metabolism
  • Drug Administration Schedule
  • Drug Interactions
  • Everolimus
  • Female
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / metabolism
  • Lisinopril / administration & dosage
  • Lisinopril / adverse effects*
  • Middle Aged
  • Sirolimus / administration & dosage
  • Sirolimus / adverse effects
  • Sirolimus / analogs & derivatives*
  • TOR Serine-Threonine Kinases / antagonists & inhibitors

Substances

  • Adrenal Cortex Hormones
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Antineoplastic Agents
  • Calcium Channel Blockers
  • Amlodipine
  • Everolimus
  • Lisinopril
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus